High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Overview:

The global high content screening market size reached US$ 1.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2028, exhibiting a growth rate (CAGR) of 8.4% during 2023-2028.

High content screening (HCS), also known as high-content analysis (HCA), is an automated microscopy method of identifying cellular phenotype and biological deviations. It assists in determining whether a drug candidate modifies the disease course and identifying micro-molecules such as peptides or RNAi that alter the cell morphology and phenotype. It is an advanced approach to cell-based screening in drug discovery, which combines the automated recording of multicolor fluorescence imaging and high-throughput quantitative data analysis. It allows professionals to screen and evaluate the activity of compounds on multiple epigenetic marks. As a result, HCS is widely used in pharmaceutical and biotechnology companies, academic and government institutes, and contract research organizations (CROS).

The increasing prevalence of chronic disorders and neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, represents one of the major factors positively influencing the demand for HCS around the world. In addition, the rising aging population, which is more prone to such ailments, is contributing to the market growth. Apart from this, leading players are introducing innovative HCS equipment that is integrated with software platforms and artificial intelligence (AI) systems to improve the visualization capabilities of the screening systems. It can also be attributed to the development of automated systems for analyzing cell separation and scalability, which has further improved the adoption of HCS technology. Furthermore, they find extensive application in the pharmaceutical industry due to the escalating need for an affordable drug discovery system. Besides this, governing agencies of numerous countries are considerably investing in the research and development (R&D) of advanced screening systems, along with significant improvement in the healthcare infrastructure, which is creating a positive market outlook.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global high content screening market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, application and end-user.

Breakup by Product:

Instruments
Cell Imaging and Analysis Systems
Flow Cytometers
Consumables
Reagents & Assay Kits
Microplates
Other Consumables
Software
Services
Accessories

Instruments dominate the market due to advances in instrumentation and automation techniques with advanced visualization capability and enhanced software platforms.

Breakup by Application:

Target Identification and Validation
Primary Screening and Secondary Screening
Toxicity Studies
Compound Profiling
Other Applications

Primary screening and secondary screening currently dominates the market as primary screening helps in determining the microorganisms and organic acid in cells, whereas secondary screening assists in obtaining the quantitative and qualitative information about the cells, desired organisms or strains.

Breakup by End-User:

Pharmaceutical and Biotechnology Companies
Academic and Government Institutes
Contract Research Organizations (CROs)

High content screening (HCS) is widely utilized in pharmaceutical and biotechnology companies for various clinical and preclinical studies.

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

North America holds the majority of the global high content screening share due to the increasing drug discovery research in the region.

Competitive Landscape:
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biotek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore, Perkinelmer Inc., Tecan Group Ltd., Thermo Fisher Scientific and Yokogawa Electric Corporation.

Key Questions Answered in This Report:
How has the global high content screening market performed so far and how will it perform in the coming years?
What are the key regional markets?
What has been the impact of COVID-19 on the global high content screening market?
What is the breakup of the market based on the product?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end-user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global high content screening market and who are the key players?
What is the degree of competition in the industry?